Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma

PRIMARY OBJECTIVES:

I. Assess the efficacy of nivolumab plus brentuximab vedotin consolidation after autologous
stem cell transplantation (ASCT) in participants with relapsed/refractory Hodgkin lymphoma
(HL), as assessed by 18-month progression-free survival (PFS).

SECONDARY OBJECTIVES:

I. Estimate the overall survival (OS), the cumulative incidence of relapse/progression, the
cumulative incidence of non-relapse mortality (TRM) in participants with relapsed/ refractory
HL who receive nivolumab plus brentuximab vedotin consolidation after ASCT.

II. Estimate the overall response rate to nivolumab plus brentuximab vedotin therapy in
participants with measurable disease after ASCT.

III. Establish the safety and tolerability of nivolumab plus brentuximab vedotin when used as
consolidation after ASCT in participants with relapsed/ refractory HL.

TERTIARY OBJECTIVES:

I. Evaluate the Lymphoma Response to Immunomodulatory therapy Criteria (LYRIC) definition of
indeterminate response to guide the management of patients regarding treatment past
progressive disease.

II. Explore the impact of nivolumab plus brentuximab vedotin therapy on immune reconstitution
after ASCT.

III. Explore the prognostic impact of and temporal dynamics of minimal residual disease (MRD)
in the peripheral blood as assessed by the next-generation sequencing-based ClonoSEQ
platform.

IV. Explore the prognostic impact of 9p24.1 abnormalities in tumor tissue assessed by
fluorescence in situ hybridization (FISH) on outcomes after ASCT and nivolumab plus
brentuximab vedotin post-ASCT consolidation therapy.

V. Explore the relationship between immune cells and Hodgkin and Reed/Sternberg (HRS) in
tumor samples by 6-color quantitative spatial image analysis using the Vectra system, and
correlate with outcome after ASCT and nivolumab plus brentuximab vedotin post-ASCT
consolidation therapy.

VI. Explore whether genetic alterations (e.g. gene expression profiles or genetic mutations)
in HL tumor samples are associated with outcome after ASCT and nivolumab plus brentuximab
vedotin post-ASCT consolidation therapy.

OUTLINE:

Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin intravenously (IV) over
30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up
to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 and 100 days, at 3, 6,
12, and 18 months from the start of treatment, and then biannually thereafter.

Inclusion Criteria:

- Documented informed consent

- Agreement to allow the use of archival tissue from pre-ASCT tumor biopsies

- If unavailable, exceptions may be granted with study principal investigator (PI)
approval

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Histologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular
lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization
(WHO) classification, with hematopathology review at the participating institution

- Have high-risk relapsed or refractory Hodgkin lymphoma (HL), defined as:

- Primary refractory disease to front-line therapy

- Relapse within 1 year of completing front-line therapy

- Extranodal involvement at the time of pre-ASCT relapse

- B symptoms at pre-ASCT relapse

- More than one type of pre-ASCT salvage therapy required

- Planning to receive or have received autologous stem cell transplantation (ACST) per
institutional standards as part of standard of care

- Pre-ASCT participants may consent but will not be eligible to begin treatment
until after ASCT, and will have to fulfill all inclusion and exclusion criteria
before starting protocol therapy

- All participants must initiate day 1 of protocol therapy within 30-60 days post
stem cell reinfusion; study PI can grant exception for a patient to start as late
as 75 days post stem cell reinfusion with a reasonable justification for delay
(e.g. recovery from post-ASCT toxicity) and this will not be a protocol
deviation, nor require an exception to be filed

- Recovery from ASCT toxicity as defined as outpatient status, able to drink, eat
normally, and do not need intravenous hydration prior to day 1 of therapy

- Achieved at least stable disease to salvage treatment determined by positron emission
tomography (PET)/computed tomography (CT) using 2014 Lugano Classification prior to
ASCT

- Brentuximab vedotin naive OR had at least stable disease by Lugano Classification to
prior brentuximab vedotin treatment

- Absolute neutrophil count (ANC) >= 1000/mm^3

- Platelets >= 50,000/mm^3

- Hemoglobin >= 8 g/dL

- Total bilirubin =< 1.5 x upper limit of normal (ULN) or 3 x ULN for Gilbert's disease

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

- Creatinine clearance >= 40 mL/min per 24 hour urine collection or the Cockcroft-Gault
formula

- Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity
(DLCO) (adjusted for Hb) >= 50% adjusted

- Women of childbearing potential (WOCBP) only: Negative urine or serum pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
[HCG])

- If the urine test is positive or cannot be confirmed as negative, a serum
pregnancy test will be required

- Woman of childbearing potential (WOCBP): use two effective methods of contraception
(hormonal or barrier method) or be surgically sterile, or abstain from heterosexual
activity for the course of the study through 7 months post last dose of nivolumab

- WOCBP defined as not being surgically sterilized or have not been free from
menses for > 1 year

- Male: use two effective methods of contraception (barrier method) or abstain from
heterosexual activity with the first dose of study therapy through 7 months post
last dose of nivolumab

Exclusion Criteria:

- Post-ASCT anti-lymphoma or investigational therapy; immediate post-ASCT consolidative
radiation therapy is allowed as long as it occurs prior to initiation of study
therapy; baseline imaging and pulmonary function tests (PFTs) must be performed after
completion of radiation

- Previous allogeneic transplant

- Total carmustine (BCNU) dose of > 600 mg/m^2 with prior treatments including
transplant conditioning regimen

- Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps,
rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], oral polio
vaccine, and oral typhoid)

- Refractory to prior brentuximab vedotin (i.e. progression while on treatment)

- Refractory to prior anti-PD-1/PD-L1 agent

- History of prior >= grade 3 hypersensitivity to either brentuximab vedotin or
nivolumab

- History of another primary malignancy that has not been in remission for at least 3
years; exceptions include:

- Basal cell carcinoma of the skin or

- Squamous cell carcinoma of the skin that has undergone potentially curative
therapy or

- In situ cervical cancer

- Known active central nervous system (CNS) involvement by lymphoma, including
parenchymal and/or lymphomatous meningitis

- History of progressive multifocal leukoencephalopathy (PML)

- Grade >= 2 peripheral neuropathy at the present time

- Prior diagnosis of inherited or acquired immunodeficiency

- Condition requiring systemic treatment with either corticosteroids (> 10 mg daily
prednisone or equivalent) or other immunosuppressive medications within 14 days of
study drug administration; exceptions are:

- Inhaled or topical steroids and

- Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of
active autoimmune disease

- Uncontrolled illness including ongoing or active infection

- History of or active pneumonitis or interstitial lung disease:

- For history of pneumonitis to be an exclusion, patient had to have required
supplemental oxygen or corticosteroid treatment; radiographic changes alone are
not an exclusion

- An active, known or suspected autoimmune disease; the following are exceptions:

- Vitiligo

- Hemolytic anemia associated with the lymphoma (history of or at the present time)

- Type I diabetes mellitus

- Residual hypothyroidism due to autoimmune condition only requiring hormone
replacement

- Psoriasis not requiring systemic treatment, or

- Conditions not expected to recur in the absence of an external trigger

- Active or known history (standard pre-ASCT assessments) of:

- Hepatitis B or C infection

- Human immunodeficiency virus (HIV)

- Acquired immunodeficiency syndrome (AIDS)

- Women who are pregnant or lactating

- History of a cerebral vascular event (stroke or transient ischemic attack), unstable
angina, myocardial infarction, or cardiac symptoms consistent with New York Heart
Association Class III-IV within 6 months prior to day 1 of protocol therapy

- History or current evidence of any condition, therapy, or laboratory abnormality that
might confound the results of the trial, interfere with the subject's participation
for the full duration of the trial, or is not in the best interest of the subject to
participate, in the opinion of the treating investigator

- Prospective participants who, in the opinion of the investigator, may not be able to
comply with all study procedures (including compliance issues related to
feasibility/logistics)